ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mitsubishi Gas Chemical (MGC) has partnered with Hokkaido System Science, a Japanese biotech research service company, to explore entering the nucleic acid contract development and manufacturing organization (CDMO) business. While MGC’s main businesses are in making chemicals, it offers R&D services as well. MGC says the nucleic acid medicine market is set for growth, and it is aiming to add the segment to its existing antibody medicine CDMO business through its new partnership.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter